To create innovative endovascular catheters for use in the treatment of patients with arterial and venous thromboembolic (A+VTE) conditions.
Orchestrate the medical profession’s identified unmet needs with our unique product development capabilities.
To create a continuous stream of new products based on the original BASHIR™ platform technology, which will improve the treatment outcomes for patients suffering from A+VTE conditions.
Founded in 2016, Thrombolex, Inc. is engaged in the design, development, manufacture and distribution of innovative endovascular catheters used in interventional procedures, particularly in catheter-directed thrombolysis (CDT) of thrombus in patients affected by A+VTE conditions.
How We Help
Thrombolex, Inc. is committed to improving the quality of life of patients with A+VTE conditions.
A+VTE are serious medical conditions that are much more widespread than is generally known by the public at large. They're conditions that have “fallen through the cracks” among various medical specialties and therefore are not diagnosed or approached with the efficiency and urgency that they merit.
The BASHIR™Endovascular Catheter is the only pharmaco-mechanical catheter cleared by the FDA. It allows for the selective infusion of physician - specified fuids, including thrombolytics, into precise locations in the patient’s peripheral vasculature. Thereby treating the thrombus more efficiently in less time, using lower doses of thrombolytic drugs, thus reducing costs.
Thrombolex is dedicated to increasing awareness of A+VTE conditions and providing the best therapy to quickly and cost-effectively reduce the clot burden, thereby improving the patient’s quality of life.
Need more details? Contact us.
We are here to assist. Contact us by phone, email or via our social media channels.